Abstract Purpose of Review The role of wnt signalling in atherogenesis raises the possibility
that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti …

The explosion in Mendelian randomization (MR) publications is hard to ignore and shows
no signs of slowing. Clinician readers, who may not be familiar with jargon-ridden methods …

Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety
remains unclear. We conducted a cis-Mendelian randomisation analysis to estimate the …

This study compared the effectiveness and cardiovascular safety of romosozumab and
teriparatide. The main finding was that there were no significant differences between the two …

Introduction The aim of this study was to investigate the cardiovascular safety of
romosozumab in postmenopausal women with osteoporosis. Romosozumab, a monoclonal …

Wnt16 is expressed in bone and arteries, and maintains bone mass in mice and humans,
but its role in cardiovascular physiology is unknown. We show that Wnt16 protein …

Metabolic syndrome (MetS), as a set of medical conditions including hyperglycemia,
hypertension, abdominal obesity, and dyslipidemia, represents a highly prevalent disease …

Sclerostin is a protein produced in osteocytes. Its production is influenced by skeletal
loading and by parathyroid hormone. It is released from the cell processes of osteocytes …

Background Romosozumab, a fully humanized anti-sclerostin-antibody, is a bone-builder
stimulating osteoblasts and inhibiting osteoclast by activation of the canonical Wnt-beta …

Cardiovascular risk assessment for osteoporosis patients considering Romosozumab -
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Help …